跳至主要内容
临床试验/NCT06065163
NCT06065163招募中不适用

Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome

Instituto Nacional de Cardiologia Ignacio Chavez2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2022年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
80
试验地点
2
主要终点
Decongestion within 7 days

研究概览

简要总结

A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

性别
All
接受健康志愿者

入选标准

  • 18 years old or older
  • Type 1 cardiorenal syndrome in emergency room at Instituto Nacional de Cardiologia Ignacio Chávez

排除标准

  • Patients who denied to participate
  • Liver disease (cirrohsis)
  • Complex congenital heart disease
  • Kidney transplant
  • Heart transplant
  • Severe valvular disease
  • Chronic kidney disease KDIGO G5 and G5d
  • INTERMACS Score 2

结局指标

主要结局

Decongestion within 7 days

时间窗: 7 days

Assess if the ultrasound guided arm achieves faster decongestion

次要结局

  • Intrahospital mortality(30 days)
  • Number of participants that initiate kidney replacement therapy(30 days)
  • Days alive out of hospital(1 month)
  • Length of hospital stay(7 days)
  • Total diuretic dose within 7 days(7 days)
  • Acutely decompensated heart failure readmission rate(7 days)

研究者

发起方
Instituto Nacional de Cardiologia Ignacio Chavez
申办方类型
Other
责任方
Principal Investigator
主要研究者

Salvador Lopez Gil

Chief of Hemodialysis Unit

Instituto Nacional de Cardiologia Ignacio Chavez

研究点 (2)

Loading locations...

相似试验